Drug Profile
Erythropoietin polysialic - Xenetic Biosciences
Alternative Names: Epolong; ErepoXen; Polysialic EPO; Polysialic erythropoietin; PSA-EPO; SYN-20070131RULatest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Lipoxen Technologies; Serum Institute of India
- Developer Serum Institute of India; SynBio; Xenetic Biosciences
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Anaemia
Most Recent Events
- 08 Oct 2021 Phase II development is still ongoing for Anaemia in India (Serum Institute of India pipeline, October 2021)
- 08 Oct 2021 No development reported - Phase-II for Anaemia in Australia (SC)
- 08 Oct 2021 No development reported - Phase-II for Anaemia in New Zealand (SC)